395 results about "Antigen-presenting cell" patented technology

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof wherein X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, optionally substituted heteroaryl, SO2NR14R15, CONR10R11 and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R14, and R15 are H or alkyl; R13 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m is 0-3. The compounds of formula (I) modulate ERAP1 (endoplasmic reticulum aminopeptidase 1) and are for use in treating proliferative, immune or inflammatory disorders, particularly cancer or leukemia. The compounds of formula (I) stimulate a neo-antigen directed immune response in the subject. A method for producing an antigen-presenting cell which presents a neo-antigen using compounds of formula (I) is disclosed. An immunogenic composition comprising an antigen-presenting cell is also disclosed. Exemplified compounds include 4-cyclopropyl-3-(N-(2-(morpholin-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid.

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The invention discloses a Toll-like receptor stimulant-based vaccine adjuvant lipid compound and application thereof, and particularly discloses a compound as shown in a formula (I), a stereoisomer thereof, an N-oxygen compound thereof, a solvate thereof or a pharmaceutically acceptable salt thereof. The mRNA-TLP composition prepared from the adjuvant lipid compound provided by the invention has significantly improved targeting to mouse spleen antigen presenting cells, and can significantly inhibit tumor growth. # imgabs0 #

The invention provides a nano-drug for treating glioma as well as a preparation method and application of the nano-drug, and particularly, the nano-drug comprises a nano-carrier and a carrier drug. The nano-drug can interact with a receptor on a brain endothelial cell, enters a brain tumor microenvironment through an endocytosis way, promotes antigen presenting cell maturation, activates T cell anti-tumor immune response, and effectively inhibits tumor growth.

A cancer therapy comprising both a population of genetically engineered T cells expressing chimeric antigen receptors (CARs) and a population of antigen presenting cells (APCs) that enhance the efficacy of the T cells expressing the CARs.

The invention discloses a tumor whole cell wrapped by a metal-polyphenol nano coating as well as a preparation method and application thereof. The preparation method comprises the following steps: step 1, fully mixing a plant polyphenol solution and a tumor cell suspension; 2, adding a manganese ion-containing compound solution, and fully mixing; 3, adding a buffer solution into the solution obtained in the step 2, fully mixing, washing, and centrifugally separating to obtain tumor cells coated with coatings; the plant polyphenol and the manganese ions can be quickly assembled at room temperature, a compact nano coating is formed on a tumor cell membrane, and tumor cells are inactivated due to the wrapping of the nano coating, so that the safety of the vaccine is ensured; the nano coating can prevent any potential tumor antigen from being lost under physiological conditions; lipopolysaccharide is further modified, so that the formed LMP whole-cell vaccine can be promoted to be endocytosed by antigen presenting cells; the metal manganese ions can stimulate the STING pathway to enhance the anti-tumor effect while forming the structural coating.

The invention belongs to the technical field of biological medicines, and particularly relates to an antigen peptide library for inducing tumor specific immune response, the antigen peptide library comprises eight antigen peptides, and the amino acid sequences of the eight antigen peptides are respectively shown as SEQ ID NO.1-SEQ ID NO.8. The invention further discloses a preparation method of the antigen peptide library. The antigen peptide has high immunogenicity and can effectively stimulate and induce generation of specific cytotoxic T lymphocytes when being loaded on antigen presenting cells, in-vitro killing experiments show that CTL cells induced and activated by loading new antigen DC have a high tumor killing effect, and the cell killing activity of the CTL cells is 90% or above. When model mice are treated by adoptive T cell back-transfusion of CTL cells induced by the new antigen peptide library, the tumor volume can be effectively reduced, the survival rate of the tumor can be remarkably increased, and good treatment potential is achieved.

The invention relates to a preparation method of a tumor microenvironment response type nano drug delivery system, which comprises the following steps: forming MnO2 nanoclusters through biomineralization induction under an alkaline condition, modifying HSA nanoparticles, then loading Ce6 through a carbodiimide method, and finally combining with a PD-L1 antibody by adopting a copper-free click chemistry method to obtain nanoparticles HMC and anti-PD-L1. The nanoparticle can be retained in a tumor tissue in a passive targeting manner through an EPR effect, and is decomposed into Mn < 2 + >, O2 and a small molecule drug through a high H2O2 and low pH microenvironment of the tumor tissue, so that the tumor permeability is greatly enhanced, the tumor immunogenicity is enhanced by combining sonodynamic therapy, the release of a tumor specific antigen and the aging of antigen presenting cells are promoted, and the tumor treatment effect is enhanced. The infiltration of tumor T cells is increased, and cold tumors are changed into hot tumors; the nanoparticles can generate O2 in situ at the same time, and the immunosuppressive ability and drug resistance caused by tumor hypoxia are overcome.

The invention relates to the technical field of biology, in particular to a tumor postoperative vaccine as well as a preparation method and application thereof. The method comprises the following steps: resuspending tumor cells in a first solution containing metal ions for incubation, collecting the tumor cells, resuspending the tumor cells in a second solution containing mineralized ions for incubation, enabling the metal ions to react with the mineralized ions to obtain metal inorganic salt, forming a mineralized shell layer on the surfaces of the tumor cells, and resuspending the tumor cells to obtain the tumor postoperative vaccine. And due to the mineralized shell layer, the vaccine has the capability of activating a signal channel in an antigen presenting cell through mechanical stimulation, so that an immune system is favorably activated, and the anti-tumor capability of the vaccine is improved. In addition, tumor cells are inactivated in the vaccine preparation process and keep a complete form, and presentation of a complete tumor antigen is facilitated, so that a relatively good anti-tumor effect is obtained.

The invention belongs to the field of nano biomedicine, and particularly discloses a yeast bionic vaccine based on a metal organic framework ZIF-8 as well as a construction method and application of the yeast bionic vaccine, and the structure of the bionic vaccine is that ZIF-8 loaded with antigen OVA is encapsulated in a yeast shell. The invention relates to preparation and anti-tumor immune response of the bionic vaccine. The yeast shell is obtained by performing acid and alkali treatment and organic solvent washing on saccharomycetes and has the effects of targeting antigen presenting cells and stimulating immune response, and the antigen-loaded metal organic framework ZIF-8 is encapsulated in the yeast shell and has relatively good stability and an effect of continuously releasing antigens. The ZIF-8 is decomposed in antigen presenting cells, and lysosome escape of the antigen is induced. The yeast bionic vaccine provided by the invention can specifically target antigen presenting cells, continuously release tumor antigens in vivo, mediate escape of lysosome of the antigens and stimulate strong anti-tumor immune response, and has a better application prospect.

The invention provides a porcine deltacoronavirus S1 protein nanoparticle vaccine CTDnps and application thereof, and belongs to the technical field of vaccine preparation. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled, provided by the invention, comprises ferritin and a PDCoV S1 protein C-terminal structural domain, the amino acid sequence of the ferritin is as shown in SEQ ID NO.1, and the amino acid sequence of the PDCoV S1 protein C-terminal structural domain is as shown in SEQ ID NO.2. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled comprises the ferritin and the PDCoV S1 protein C-terminal structural domain. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine (S1CTD-Fer) constructed by the invention can be self-assembled to form ferritin-like cage-shaped nanoparticles, and the hydrodynamic diameter of the cage-shaped nanoparticles is obviously greater than that of natural ferritin nanoparticles. Compared with the S1CTD, the S1CTD-Fel based on the ferritin carrier can obviously enhance the immunogenicity of the S1CTD, can obviously enhance the uptake efficiency of antigen presenting cells, and is high in safety.

The invention discloses a tumor nano vaccine (BAPs) of bionic autophagosome as well as a preparation method and application thereof, and the vaccine effectively stimulates anti-tumor immunity by precisely fusing a neoantigen derived from the autophagosome and an immunologic adjuvant targeted lymph node. The BAPs with the redox response characteristic promote the vaccine to be opened in antigen presenting cells, so that an adjuvant and an antigen are exposed, and a strong immune response is stimulated. The BAPs can excite wide T cell reactions, and finally, more than 70% of established tumors are effectively eliminated. BAPs vaccination initiates a lasting T cell reaction and provides powerful protection, all mice are protected in tumor recurrence challenge, and the tumor incidence rate is significantly reduced by nearly 90%. In addition, the BAPs and a checkpoint inhibition therapy have a synergistic effect, and growth of breast cancer with poor immunogenicity is inhibited. The BAPs nano vaccine provides an efficient strategy with clinical transformation potential to enhance the strong immune response of personalized cancer immunotherapy.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

The invention provides an mRNA (messenger Ribonucleic Acid) or mRNA-LNP (Leucine Natriuretic Peptide) compound for coding antibody-antigen fusion protein and application thereof, and belongs to the technical field of cell therapy. Wherein the coding frame sequence of the mRNA comprises an antibody sequence, a cleavage sequence and an antigen peptide sequence; wherein the antibody targets a tumor high-expression surface protein, and the antigen is a high-immunogenicity antigen. According to the mRNA-coded antibody-antigen fusion protein, high-expression protein on the surface of a tumor cell is specifically recognized through an antibody, and a high-immunogenicity antigen is introduced into a recognized tumor target cell to mark the tumor cell. The mRNA can be ingested, processed and presented by antigen presenting cells so as to stimulate and activate antigen-specific TCR-T cells in vivo. Therefore, the widely labeled tumor cells can be specifically recognized and killed by the antigen-specific TCR-T cells in vivo.

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6 / 7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6 / 7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6 / 7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

The invention discloses a degradable polycarbonate cationic carrier and application thereof, and belongs to the technical field of drugs, the degradable polycarbonate cationic carrier is a nano-micelle formed by self-assembly of diblock polymers, the diblock polymers are represented as A-B, the A block is mPEG, and the B block is PAMA, PDMA or PDEA; the molecular weight of the block A is 2000 to 5000, and the polymerization degree of the block B is 50 to 150. The degradable polycarbonate cation carrier has an mRNA delivery function, and is combined with mRNA through a positive and negative electricity interaction principle, so that the problem of gene waste caused by mRNA loading through a microfluidic method can be solved, and efficient delivery of antigen presenting cells (APC) is realized.

The invention relates to the technical field of biological medicine, and provides a Chinese herbal medicine vesicle-LNP hybrid tumor mRNA vaccine and application thereof. The tumor mRNA vaccine disclosed by the invention is obtained by hybridizing Chinese herbal medicine nano-vesicles and lipid nano-particles loaded with tumor antigen mRNA. According to the invention, the characteristic of good biocompatibility of Chinese herbal medicines is utilized, so that the safety risk of the cationic lipid carrier is reduced. By combining the characteristics of Chinese herbal medicines, the nano-vesicles are extracted, so that the LNP is promoted to more effectively target antigen-presenting cells, the uptake level of the antigen-presenting cells is promoted, the phagocytosis of mRNA is enhanced, and the targeting and transcriptional expression level of mRNA can be enhanced. Finally, the Chinese herbal medicine nano vesicle-LNP hybrid tumor mRNA vaccine can strengthen the curative effects of inhibiting tumor progression, tumor recurrence and tumor metastasis after the tumor mRNA vaccine is inoculated, and a path is opened up for the combination of the tumor mRNA vaccine and richer immunotherapy means.

Disclosed are a metal-polyphenol nano-coating-wrapped tumor whole cell, a preparation method therefor, and use thereof. A plant polyphenol in the present invention and manganese ions can be rapidly assembled at room temperature to form a dense coating on the membrane of a tumor cell. The nano-coating wrapping inactivates the tumor cell, ensuring that the vaccine is safe. The nano-coating can prevent any potential tumor antigen from being lost under physiological conditions. The nano-coating is further modified with a lipopolysaccharide, which can promote the endocytosis of the formed whole-cell vaccine by antigen-presenting cells. While forming the structural coating, ions of the metal manganese can stimulate the STING pathway to enhance the anti-tumor effect.

The invention discloses a ternary carrier-free nanoparticle as well as a preparation method and application thereof. The ternary carrier-free nanoparticles comprise nanoparticles which are formed by the chlorine e6, the lonidamine and the RG108 through an intermolecular interaction force. The nanoparticles can improve effective absorption and accumulation of drugs in tumors, can induce tumor specific pyroptosis and immunogenic effect under laser irradiation, and can promote maturation of antigen presenting cells and recruitment and activation of cytotoxic T lymphocytes, thereby starting adaptive anti-tumor immunity.

The present invention provides epitope peptides which are derived from SARS-CoV-2 proteins and have the ability to induce cytotoxic T cells. The present invention also provides polynucleotides encoding the peptides, antigen-presenting cells that present the peptides, and cytotoxic T cells that target the peptides, and methods of inducing the antigen-presenting cells or CTLs. The present invention further provides compositions and pharmaceutical compositions containing them as active ingredients. Moreover, the present invention provides methods of treating and / or preventing coronavirus infectious diseases, and / or suppressing the aggravation of coronavirus infectious diseases by using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells, or pharmaceutical compositions of the present invention. The present invention also provides methods of inducing an immune response against coronavirus infection. Furthermore, the present invention provides methods of examining the history of coronavirus infection by detecting TCR sequences of a subject.

Two plasmids are transformed in the bacterium, one plasmid is a gene editing plasmid which is used for expressing CRISPR / Cas9 gene editing tools in the bacterium, the sgRNA sequence is shown in SEQ ID NO.1, and the other plasmid is an X174E-CKS9 expression plasmid which is used for expressing targeting peptide shown in SEQ ID NO.2 and IPTG (isopropyl-beta-d-thiogalactoside) induced expression splitting gene X174E in the bacterium. The invention further discloses a cracking vesicle obtained after induction of the engineering bacterium and application of the cracking vesicle. CKS9-loaded lysing vesicles with M cell targeting are generated in situ, and a gene editing tool is transferred to antigen presenting cells by using the characteristic that the M cells can completely transfer antigens to lymphatic follicles. Compared with a strategy of mannose modification and other targeted antigen-presenting cells, the method has the advantages that the targeting property is more accurate, and a new choice is provided for the antigen-presenting cells of targeted intestinal tracts.

Abstract Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell. Abstract 2018 / 22761 oM - cell Target ml Target cell cell cell Target Target Target SUBSTITUTE SHEET (RULE 26) cell cell cell Target Target cell cell 1 / 28 my Isolate recognized cell Library of target cells target cells and displaying different Add T cells from sample sequence antigens antigens of interest. CTLs deliver cytotoxic granules to target cells displaying cognate antigen FIG. 1 PCT / US2018 / 036663 20 26 20 53 56 07 J ul 2 02 6 2 0 2 6 2 0 5 3 5 6 0 7 J u l 2 0 2 6 2 0 1 8 / 2 2 7 6 1 o M a n d m y 1 / 2 8 m y L i b r a r y o f t a r g e t c e l l s d i s p l a y i n g d i f f e r e n tA d d T c e l l s f r o m s a m p l e of interest. CTLs deliver c y t o t o x i c g r a n u l e s t o t a r g e t c e l l s d i s p l a y i n g c o g n a t e a n t i g e n P C T / U S 2 0 1 8 / 0 3 6 6 6 3

The present application provides enhanced APCs for use in the treatment of HPV-associated cancers. The enhanced APC is capable of activating T cells in an HLA-agnostic manner and is derived from an input APC in which at least one nucleic acid encoding an HPV antigen has been delivered within the cell. In some aspects, the enhanced APC is administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1 / PD-L1 and / or an antagonist of CTLA-4.

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV / Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV / Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV / Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV / Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.

The invention belongs to the technical field of cancer immunotherapy, and particularly relates to iterative radiation-resistant tumor cell debris, a preparation method thereof and an application thereof in tumor resistance. The anti-radiation tumor cells generated by repeated radiation exposure show higher TMB (Tetramethylbenzidine) and induce stronger immunoreaction, so that a personalized vaccine is developed based on the method, and the frozen fragment vaccine is obtained by freeze thawing and inactivation of the radiation-resistant tumor cells. The RR-FDV exhibits enhanced immunogenicity as compared to a conventional radiosensitive counterpart. In the present disclosure, RR-FDV exhibits superior activation of antigen presenting cells, while in vivo, it recruits more dendritic cells to the vaccination site, promotes DC-mediated antigen presentation, and induces stronger antigen-specific T cell toxicity.

The invention discloses a nucleic acid vaccine based on different forms of nano-aluminum adjuvants and application thereof, the nucleic acid vaccine is composed of an inner core, a middle layer and a shell from inside to outside in sequence, the inner core is a compound of a cationic polymer and nucleic acid, the middle layer is an anionic polymer, and the shell is a continuous or discontinuous nano-aluminum coating layer. The nano-aluminum-coated nucleic acid delivery system provided by the invention is used for preparing vaccines, can effectively activate antigen presenting cells and promote antigen presentation, so that humoral immunity and cellular immunity processes of an organism are simultaneously activated, the tumor immunotherapy effect is enhanced, and the nano-aluminum-coated nucleic acid delivery system has relatively high clinical use value.

The invention relates to allograft tolerance without systemic immune containment. There is provided a cell genetically modified to comprise at least one mechanism for providing localized immune containment at a transplantation site when transplanted into an allogeneic host; and methods for making and using the cells. The cell comprises a set of transgenes, each transgene encoding a gene product of cytoplasm, membrane binding or topical action, and having one or more of the following functions: mitigating antigen presenting cell activation and function; mitigating leukocyte activity or cytolytic function of the aggressive graft; the cytolytic function and phagocytosis of macrophages of allograft cells are reduced; inducing apoptosis in the graft-attacking leukocytes; reducing local inflammatory proteins; and protecting from leukocyte mediated apoptosis.

There is an urgent need for an effective therapeutic vaccine against tuberculosis (TB), which remains a major public health problem. Current "classical" strategies under development have failed or are suboptimal, and more effective vaccines are needed to achieve the World Health Organization's 2035 End TB Strategy. We have generated a post-exposure / therapeutic TB vaccine candidate (CD40.TB) whose heavy chain consists of an antibody directed against a surface antigen (i.e., CD40) of antigen-presenting cells (i.e., dendritic cells) conjugated to three relevant Mycobacterium tuberculosis (Mtb) antigens and which is liable to induce potent anti-TB humoral and cellular immunity.

Devices and methods for obtaining immunostimulatory antigen presenting cells. The present invention relates to methods for producing immunostimulatory antigen presenting cells. The invention also relates to the use of such cells for treating a patient suffering from a hyperproliferative disease, such as cancer.

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 strain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and / or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.